FREQUENTLY ASKED QUESTIONS
Miranda Baumgartner Vaccines for Children/QI Coordinator

- A question commonly asked of the Immunization Program will be presented.
- All participants will be given a short time to discuss and think about the question.
- Next the answer will be discussed.

TODAY’S PRESENTATION

DOES AN OPEN VIAL OF IPV NEED TO BE DISCARDED AFTER 30 DAYS?
• Vaccines in multidose vials that do not require reconstitution can be used through the expiration date printed on the label as long as the vaccine is not contaminated unless indicated otherwise by the manufacturer.
• IPV in a multidose vial can be used through the expiration date on the vial.
• The Centers for Disease Control and Prevention (CDC) Immunization Program states that vaccines are to be discarded per the manufacturer’s expiration date. The Joint Commission applies this approach to all vaccines - whether a part of the CDC or state immunization program or purchased by healthcare facilities - with the expectation that vaccines are managed in accordance with the product manufacturer’s instructions for use (correct temperature, frequency of temperature checks, etc.) and any applicable regulatory requirements.

OPEN MULTIDOSE VIALS (CONT.)

• For some vaccines, the manufacturer specifies that once the multidose vial has been entered or the rubber stopper punctured, the vaccine must be used within a certain number of days. This information will be found in the vaccine package insert.
• This is commonly referred to as the "beyond-use date" (BUD). Specific information regarding the BUD can be found in the product information.

THE INFLUENZA VACCINE WE CARRY STATES A DOSE IS 0.5ML. DO CHILDREN 6 TO 35 MONTHS RECEIVE A HALF DOSE?
Influenza vaccine is recommended for all patients 6 months and older.

- All children 6 months through 8 years that have not received two doses of influenza vaccine prior to July 1, 2021 will need to receive two doses this influenza season.

Influenza vaccine:

- Afluria® is a 0.25 mL dose for patients 6 to 35 months.
- Fluarix® is a 0.5mL dose for all patients 6 months and older.
- FluLaval® is a 0.5mL dose for all patients 6 months and older.
- Fluzone® is a 0.5mL dose for all patients 6 months and older.
- Flucelvax® is a 0.5mL dose for 6 months and older.
- Flumist® is a 0.2mL dose for 2 to 49 years.

THE CLINIC PLACED A VACCINE ORDER LAST WEEK FOR HPV, INFLUENZA AND VARICELLA VACCINES. TODAY YOU ONLY RECEIVED THE INFLUENZA VACCINE. WILL THE HPV AND VARICELLA VACCINE BE COMING?
VACCINE SHIPMENTS

- All vaccine orders can be reviewed in the order tab in NDIIS.
- Influenza, Varicella and MMRV vaccine, regardless if ordered with other vaccines, will be shipped separately.
- Allow 2 to 3 weeks for delivery of all other vaccines.

IS MENACTRA® BEING DISCONTINUED?

- Protective against invasive meningococcal disease caused by Neisseira meningitidis types A, C, Y, and W-135.
- Approved for ages 2 years and older.
- Menactra® will be discontinued.
- The remaining Menactra® supply may be available until mid-2022.
- Providers offering Menactra® should make a transition plan.
- Menveo® is still available through the VFC program.
HOW DO PROVIDER OFFICES REQUEST FOR DUPLICATE NDIIS RECORDS TO BE COMBINED?

- Flag any duplicate records in the NDIIS by typing the word “DUPLICATE” on an empty field of the Demographics page.
- Do NOT delete any demographic information from the NDIIS record!
- Make sure patient names are spelled the same in the NDIIS and in your EHR whenever possible.
- Do not use nicknames in first name field.

CLIENT DE-DUPLICATION

What the NDIIS Does:
- Automated client deduplication looks at all client records touched the previous day and scans the NDIIS for potential duplicate records.
- Any potential duplicates are placed in queue for daily manual review by the immunization program.
- Run a weekly report to look for duplicate client records flagged by NDIIS users and merge duplicates.

What You Can Do:
- Flag any duplicate records in the NDIIS by typing the word “DUPLICATE” on an empty field of the Demographics page.
- Do NOT delete any demographic information from the NDIIS record!
- Make sure patient names are spelled the same in the NDIIS and in your EHR whenever possible.
- Do not use nicknames in first name field.

FLAGGING DUPLICATE CLIENT RECORDS

- The word “DUPLICATE” must be spelled correctly.
- Entering words such as “merge” or “wrong” will not flag duplicate records on the immunization program report and they won’t be merged.
VACCINE DE-DUPLICATION

What the NDIIS Does:
- Automated vaccine deduplication evaluates every dose as it is being entered in the NDIIS and automatically removes obvious duplicates.
- Removes approximately 85% of duplicate doses automatically and immediately.
- Doses that cannot be easily identified as a duplicate are placed in a queue to be evaluated by immunization program staff.

What You Can Do:
- Delete duplicate historical doses and duplicate doses entered by your provider site.
- If doses left in a record after deleting a duplicate are invalid, contact the immunization program to have the doses set back to valid.
- If there are duplicate doses in a record you cannot delete, contact the immunization program to have the duplicates removed.

IN THE NDIIS VACCINE ORDERING MODULE HOW ARE THE DOSES ADMINISTERED CALCULATED?

- In NDIIS, the doses administered used to calculate the suggested order minimum (which is a one month supply) and the suggested order maximum (which is a three month supply) are based on the previous months doses administered.
- The ordering module does not take into account any doses that would have been given during the current calendar month.
- The inventory used to calculate the suggested order minimum and maximum is based on the provider office current inventory.
NDIIS VACCINE INVENTORY

- The NDIIS inventory on the ordering screen may not reflect what is currently on hand at provider offices unless the provider has reconciled their inventory.
- NDIIS vaccine order suggested min and max are created based on the inventory that the provider enters when placing a vaccine order.

WHEN DOCUMENTING VACCINE ADMINISTRATION, SHOULD THE LOT NUMBER FROM THE BOX OR THE VIAL BE USED?

- The Unit of Sale (UoS) is the exterior packaging or carton that the vaccine is shipped in.
- The Unit of Use (UoU) is the vaccine vial or pre-filled syringe found within the UoS.

VACCINE LOT NUMBERS
The UoS is generally the lot number used for inventory management and it is the lot number that the Division of Immunizations receives from the CDC shipping logs and enters into the NDIIS vaccine inventory.

The lot numbers available during dose data entry are only those lot numbers currently in the provider’s NDIIS inventory, which are from the UoS. When the correct lot number is selected during dose entry, the dose will be decremented from the provider’s inventory and will be tracked as either a public or private dose administered.

If the lot number entered into the EHR is from the UoU and not the UoS, a matching lot number cannot be found in the NDIIS and a dummy dose will be added to the client immunization record in place of the actual administered lot number. Without a matching lot number found in the NDIIS and added to the record, the dose cannot be decremented from the provider’s inventory and will not be correctly tracked as either a public or private dose administered.

A help guide can be found in the help menu in NDIIS.
If providers are scanning the vaccine vial the missing character can be added to the documentation in the EMR.

VACCINE LOT NUMBERS

IF A PROVIDER OFFICE HAS INFLUENZA VACCINE ON HAND AND THEY ARE DONE VACCINATING CAN THEY SEND THE VACCINE BACK NOW?

Viable vaccine that has not expired cannot be sent back to McKesson until the vaccine expires.

Vaccine should be kept on hand for those patients that may need a dose.

The Division of Immunizations can be contacted in the case that you have extra vaccine on hand in the instance a provider is in need of vaccine.
THE CLINIC RECEIVED A NON-VIABLE SHIPMENT FROM MERCK. THE CLINIC WORKED WITH MERCK TO RETURN THE VACCINE AND GET A REPLACEMENT SHIPMENT BUT NOW WHAT STEPS DO I NEED TO TAKE?

- Information only applies to vaccine deemed nonviable upon delivery due to length of shipment, out of range temperatures upon delivery etc. This does not apply to expired or otherwise nonviable vaccines.
- With the exception of replacement shipments the Division of Immunizations receives all lot number information from Merck and McKesson as soon as vaccine is shipped from their warehouses.
- We do not receive this information for replacement shipments so NDC code, lot number, expiration and quantity must be reported to the immunization program as soon as the vaccine arrives.
- The non-viable vaccine (original shipment) should then be entered into NDIIS as a WASTAGE.
- A return in NDIIS will generate a packing slip and a pre-paid return label to send the vaccine back to McKesson.
- A wastage will remove the vaccine from your inventory but not generate materials for the vaccine to be returned as Merck will provide the materials needed for a return.

VACCINE REPLACEMENT SHIPMENTS

- Are you able to order more COVID19 vaccine ancillary supplies if needed?
COVID19 VACCINE ANCILLARY SUPPLIES

- COVID19 vaccine ancillary supplies have not changed in package quantity to accommodate booster/3rd doses.
- Extra COVID19 vaccine ancillary supplies need to be ordered through HAN assets [http://hanassets.nd.gov/](http://hanassets.nd.gov/).

HOW DO I KNOW WHICH INFLUENZA PRESENTATION TO ENTER INTO NDIIS FOR MY VACCINE?

- In the NDIIS help menu there is a flu abbreviation chart that will assist you with entering vaccine into the lot management section of NDIIS.
NDIIS LOT MANAGEMENT

- Choosing the correct presentation is important from the dropdown list.
- This is also important in data entry of historical doses into NDIIS.

HOW CAN I TELL APART ALL THE COVID19 VACCINE PRESENTATIONS IN NDIIS?

- Each COVID19 vaccine has their own NDIIS description.
  - COVID19 Pfizer– current purple cap
  - COVID19 Pfizer 12 plus– NEW grey cap
  - COVID19 5-11 years – Current orange cap
  - COVID19 Janssen – J&J vaccine
  - COVID19 Moderna– Current Moderna vaccine
OUR CLINIC HAS BEGUN STOCKING FLUAD® FOR PEOPLE 65 AND OLDER? IS THIS A HIGH DOSE INFLUENZA VACCINE?

- Fluad® is an adjuvanted influenza vaccine for adults 65 years and older. This vaccine is NOT a high-dose influenza vaccine.
- Fluad® contains an adjuvant (additive) that helps create a stronger immune response. This has shown to have a significantly higher immune response than those who receive a standard influenza dose.
- Fluzone® High-Dose is the only licensed high-dose inactivated influenza vaccine.
- Contains four times the amount of antigen as a regular influenza vaccine to help produce a stronger immune response in adults 65 years and older.

INFLUENZA VACCINE

CAN THE PEDIATRIC PFIZER BE STORED IN THE FREEZER?
Vaccine can be stored:
- Ultra-cold freezer at temperatures of -90 to -60°C (-112 to -76°F) for up to 6 months in the trays.
- Refrigerator at 2°C to 8°C (36°F to 46°F) for up to 10 weeks in the Pfizer tray or another tray. **DO NOT REFREEZE VACCINE.**

PEDIATRIC PFIZER

**Room temperature for no more than 12 hours prior to dilution,** this is cumulative time for each vial. At that time vaccine will need to be placed in the refrigerator. After dilution vaccine can either be stored in the refrigerator or at room temperature.

PEDIATRIC PFIZER

Vaccine thawing prior to administration:
- Thaw for up to 4 hours at 2°C to 8°C (36°F to 46°F) or 30 minutes at room temperature
- Using either thawing method, vials must reach room temperature before dilution and must be diluted within 12 hours or placed in the refrigerator
- **Punctured vials need to be discarded after 12 hours**
WHO SHOULD RECEIVE A COVID19 VACCINE BOOSTER DOSE?

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Minimum Time After Second Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moderna</td>
<td>6 months</td>
</tr>
<tr>
<td>Pfizer</td>
<td>6 months</td>
</tr>
<tr>
<td>Janssen</td>
<td>2 months</td>
</tr>
</tbody>
</table>

COVID19 VACCINE BOOSTER DOSES

- COVID19 vaccine booster doses are indicated for all persons 18 year and older.
- Moderna and Pfizer booster should be 6 months after second dose.
- Janssen booster dose at least 2 months after your first dose.
- Moderna booster are 0.25mL
ARE COVID19 VACCINES INTERCHANGEABLE?

- All doses of the primary series and the additional primary dose should be completed with the same vaccine product.
- If two doses of different mRNA COVID-19 vaccine products are administered in these situations (or administered inadvertently), the primary series is considered complete, and no subsequent doses of either product are recommended to complete the primary series.

COVID19 VACCINES

- All doses of the primary series and the additional primary dose should be completed with the same vaccine product.
- If two doses of different mRNA COVID-19 vaccine products are administered in these situations (or administered inadvertently), the primary series is considered complete, and no subsequent doses of either product are recommended to complete the primary series.

CAN COVID19 VACCINE BE ADMINISTERED WITH OTHER VACCINES?

- All doses of the primary series and the additional primary dose should be completed with the same vaccine product.
- If two doses of different mRNA COVID-19 vaccine products are administered in these situations (or administered inadvertently), the primary series is considered complete, and no subsequent doses of either product are recommended to complete the primary series.
COADMINISTRATION OF VACCINES

- COVID19 vaccines may be administered without regard to timing of other vaccines. This includes simultaneous administration of COVID19 vaccine and other vaccines on the same day.
- If multiple vaccines are administered at a single visit, administer each injection in a different injection site.

ARE THERE CASES WHEN YOU SHOULD REPEAT COVID19 VACCINE DOSE?
<table>
<thead>
<tr>
<th>Scenario</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scenario 1</td>
<td>Descriptive text about Scenario 1.</td>
</tr>
<tr>
<td>Scenario 2</td>
<td>Descriptive text about Scenario 2.</td>
</tr>
<tr>
<td>Scenario 3</td>
<td>Descriptive text about Scenario 3.</td>
</tr>
<tr>
<td>Scenario 4</td>
<td>Descriptive text about Scenario 4.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Constraint</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Constraint 1</td>
<td>Descriptive text about Constraint 1.</td>
</tr>
<tr>
<td>Constraint 2</td>
<td>Descriptive text about Constraint 2.</td>
</tr>
<tr>
<td>Constraint 3</td>
<td>Descriptive text about Constraint 3.</td>
</tr>
<tr>
<td>Constraint 4</td>
<td>Descriptive text about Constraint 4.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Requirement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Requirement 1</td>
<td>Descriptive text about Requirement 1.</td>
</tr>
<tr>
<td>Requirement 2</td>
<td>Descriptive text about Requirement 2.</td>
</tr>
<tr>
<td>Requirement 3</td>
<td>Descriptive text about Requirement 3.</td>
</tr>
<tr>
<td>Requirement 4</td>
<td>Descriptive text about Requirement 4.</td>
</tr>
</tbody>
</table>
For vaccine orders placed by Friday, December 10th shipping before January 2022 should take place.

There will be very limited shipping after December 13th and vaccines ordered after that day may not arrive until January 2022.
COVID19 VACCINE SHIPPING SCHEDULE

- Due to the holiday there will be limited COVID19 vaccine direct shipments. No direct shipments will take place December 23rd through December 27th and December 30th through January 3rd.
- There will be direct shipments on December 28th and 29th.
- Vaccine shipments will still continue from the warehouse with the exception of December 24th and December 31st.
- Normal direct shipping will resume on January 4th.
- CDC has advised that orders submitted during the week of December 13th will ship prior to the holiday blackout.
### NORTH DAKOTA IMMUNIZATION PROGRAM

<table>
<thead>
<tr>
<th>Position</th>
<th>Name</th>
<th>Phone</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program Manager</td>
<td>Molly Howell, MPH</td>
<td>701.328.6544</td>
<td><a href="mailto:mahowell@nd.gov">mahowell@nd.gov</a></td>
</tr>
<tr>
<td>Nurses/Quality Improvement Manager</td>
<td>Mary Wolsowerz, MA</td>
<td>701.238.2406</td>
<td><a href="mailto:mary.wolsowerz@nd.gov">mary.wolsowerz@nd.gov</a></td>
</tr>
<tr>
<td>VFC/Quality Improvement Manager</td>
<td>Rachel Gettel, MPH</td>
<td>701.328.7323</td>
<td><a href="mailto:rgettel@nd.gov">rgettel@nd.gov</a></td>
</tr>
<tr>
<td>NDVIS Coordinator</td>
<td>Jennifer Galbreth</td>
<td>701.328.3105</td>
<td><a href="mailto:jgalbreth@nd.gov">jgalbreth@nd.gov</a></td>
</tr>
<tr>
<td>ND DIIS Coordinator</td>
<td>Abbi Berg, MPH</td>
<td>701.328.3324</td>
<td><a href="mailto:alberg@nd.gov">alberg@nd.gov</a></td>
</tr>
<tr>
<td>ND DIIS Coordinator</td>
<td>Rachel Gettel, MPH</td>
<td>701.328.7323</td>
<td><a href="mailto:rgettel@nd.gov">rgettel@nd.gov</a></td>
</tr>
<tr>
<td>ND DIIS Coordinator</td>
<td>Jennifer Galbreth</td>
<td>701.328.3105</td>
<td><a href="mailto:jgalbreth@nd.gov">jgalbreth@nd.gov</a></td>
</tr>
<tr>
<td>ND DIIS Coordinator</td>
<td>Abbi Berg, MPH</td>
<td>701.328.3324</td>
<td><a href="mailto:alberg@nd.gov">alberg@nd.gov</a></td>
</tr>
<tr>
<td>ND DIIS Coordinator</td>
<td>Rachel Gettel, MPH</td>
<td>701.328.7323</td>
<td><a href="mailto:rgettel@nd.gov">rgettel@nd.gov</a></td>
</tr>
<tr>
<td>ND DIIS Coordinator</td>
<td>Jennifer Galbreth</td>
<td>701.328.3105</td>
<td><a href="mailto:jgalbreth@nd.gov">jgalbreth@nd.gov</a></td>
</tr>
<tr>
<td>ND DIIS Coordinator</td>
<td>Abbi Berg, MPH</td>
<td>701.328.3324</td>
<td><a href="mailto:alberg@nd.gov">alberg@nd.gov</a></td>
</tr>
</tbody>
</table>

### POST-TEST

- **Post-test**
  - Nurses interested in continuing education credit, visit https://ndhealth.co1.qualtrics.com/jfe/form/SV_d8z2aW6GnmgiVMy
  - Successfully complete the five-question post-test to receive your certificate
  - Credit for this session available until January 12, 2022
  - This presentation will be posted to our website: www.ndhealth.gov/immunize